Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3500
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
August 16, 2023
Cybin’s New US Patent Covers Proprietary Deuterated Psychedelic Analogs
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
6 Analysts Have This to Say About Cybin
August 15, 2023
Via
Benzinga
Cybin's Q1 2023 Financials, Deuterated Psychedelics Moving 'Steadily' Through The Clinic
August 14, 2023
Canadian clinical-stage psychedelics company Cybin (NYSE: CYBN) shared its unaudited financial results for the first quarter ended June 30, 2023:
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M
August 04, 2023
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units
Via
Benzinga
Analyst Expectations for Cybin's Future
July 03, 2023
Via
Benzinga
Cybin: Q4 Earnings Insights
June 27, 2023
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 01, 2023
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list.
Via
Benzinga
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
August 01, 2023
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for...
Via
Benzinga
US Stocks Mixed; Pfizer Earnings Beat Views
August 01, 2023
U.S. stocks were mixed this morning, with the Dow Jones trading slightly higher on Tuesday. Following the market opening Tuesday, the Dow traded up 0.03% to 35,568.68 while the NASDAQ fell 0.57% to...
Via
Benzinga
Why TETRA Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
August 01, 2023
Gainers American Superconductor Corporation (NASDAQ: AMSC) shares surged 112.1% to $21.38 in pre-market trading. AMSC is expected to report first-quarter results on Aug. 9, 2023.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 01, 2023
It's time for a look at the biggest pre-market stock movers as we check out the latest news worth reading on Tuesday morning!
Via
InvestorPlace
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
July 24, 2023
Cybin One Steps Away From Complete Dosing
Via
Benzinga
A Quantum Leap In Psychedelic Research: Study Shows Real-Time Brain Changes After Ketamine Use
July 21, 2023
A newly published study shows that Kernel’s Flow technology system is in fact able to capture and analyze brain changes following the administration of a psychoactive substance.
Via
Benzinga
Why Caribou Biosciences Shares Are Trading Higher By Around 58%? Here Are Other Stocks Moving In Thursday's Session
July 06, 2023
Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity investment from Pfizer.
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
June 28, 2023
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5...
Via
Benzinga
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
June 06, 2023
Major Investor Commits $30 Million To Psychedelics Funding
Via
Benzinga
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
June 01, 2023
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May.
Via
Talk Markets
Major Investor Commits $30M To Psychedelics Funding
May 31, 2023
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
June 06, 2023
On Tuesday, 69 stocks hit new 52-week lows.
Via
Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
May 24, 2023
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing
Via
Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
May 09, 2023
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug...
Via
Benzinga
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.